Scientific Sessions
  • #AHA22
  • Virtual Experience Access
  • Sessions Posters
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Featured Exhibitors
  • Program
  • Previews
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Featured Exhibitors
  • Program
  • Previews
Resources
  • #AHA22
  • Virtual Experience Access
  • Sessions Posters
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter iconFacebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
Nov 14th, 2020

COVID-19 Rapid Response Research Consortium yields early results


Getty Images 1215930799

In the early phases of the pandemic, when reports from China and Italy revealed that COVID-19 patients were developing cardiovascular and stroke complications, the American Heart Association quickly responded.

“We felt a real urgency to provide credible evidence to try to understand what was going on,” said Robert A. Harrington, MD, FAHA, the AHA’s immediate past-president.

With $2.5 million made available for the cause, the AHA requested rapid response grant proposals. A few weeks later, the association received more than 750 applications. 

After selecting 16 awardees and four health tech and innovation Strategically Focused Research Network supplemental awards, Dr. Harrington said the AHA set out to do what it does best — respond with science to public health issues. 

Early results from five of the 16 studies were highlighted during the “AHA Rapid Response Grant COVID-19 and its Cardiovascular Impact” session Friday:  

  • COVID-19 infection, African American women and cardiovascular health
    Michelle A. Albert, MD, MPH, professor and associate dean of admissions at the University of California at the San Francisco School of Medicine, said that Black women are experiencing not just a pandemic, but a “syndemic,” or synergistic epidemic — a combination of COVID-19 and the resulting exacerbation of social inequalities caused by systemic racism in the United States. Black people are dying from COVID-19 at higher rates than others, and yet Black women who are reporting more unfair medical treatment are displaying higher resilience (in factors such as emotional regulation and self-reliance) than their White counterparts, said Dr. Albert, the 2020 recipient of the AHA’s Population Research Prize. 
  • Harnessing glycomics to understand myocardial injury in COVID-19
    Rebekah L. Gundry, PhD, professor, director of the CardiOmics program and assistant chief for basic and translational research in cardiovascular medicine at the College of Medicine at the University of Nebraska Medical Center, presented glycans research as it relates to COVID-19 and the heart. By harnessing the glycome and extracting data, Dr. Gundry said she hopes to identify signatures in the blood that predict which patients will be more susceptible to COVID-19 infection and post-viral cardiovascular disease as well as inform mechanisms of myocardial injury. 
  • Repurposing drugs for COVID-19
    Joseph Loscalzo, MD, PhD, head of the Department of Medicine at Brigham and Women’s Hospital and Harvard Medical School, displayed visuals of a COVID-19 disease module, dubbed the “Cardiac Covidome.” It shows 322 human proteins to which 26 SARS-CoV-2 proteins bind. Possible repurposed drugs then must target proteins within the Covidome or very near it to be effective in treatment. One of four disease modules that overlap with the Covidome is that for obesity, Dr. Loscalzo said. 
  • SARS-CoV-2 and ACE2: Viral susceptibility and drugs 
    Michael Bristow, MD, PhD, professor of medicine and cardiology at the University of Colorado School of Medicine, has been working with ACE2 for almost 25 years and is now studying its role as a SARS-CoV-2 receptor for cell entry. In conjunction with Gregory Bix, MD, PhD, FAHA, the director of the Clinical Neuroscience Research Center at Tulane, he is analyzing the roles of the integrin-binding peptide, ATN-161, as a novel therapy. 
  • COVID-19 and thromboembolism
    Jane E. Freedman, MD, cardiologist at the University of Massachusetts Medical School, said patients with COVID-19 are at an increased risk of thrombosis, with thrombotic events occurring in 16% of patients studied. “Treatment is complicated, because it appears to be a diffuse collection of arterial and venous thrombotic diseases,” Dr. Freedman said. She’s studying the role of antiplatelet agents. 

To learn more about the AHA COVID-19 Rapid Response Research Consortium and other funded research projects, visit https://professional.heart.org/en/research-programs/aha-rapid-response-grant-covid19.

 

Interesting Stories
New Double Take Videos from NEJM
Sponsored by NEJM Group
New Double Take Videos from NEJM
Modern Wearable Defibrillation
Sponsored by Kestra Medical Technologies
Modern Wearable Defibrillation
Data-driven precision medicine
Sponsored by Tempus
Data-driven precision medicine
MiCare Path joins the AHA CHTI and will integrate AHA science-based
Sponsored by MiCare Path
MiCare Path joins the AHA CHTI and will integrate AHA science-based
More Content
Manesh Patel
AHA22
#AHA 22 Closing Session: That’s a wrap
Nov 9th, 2022
Getty Images 1388100332
AHA22
Congratulations to the winners of the Wellness Challenge and Scavenger Hunt
Nov 8th, 2022
puppy snugglers
AHA22
Special Recognition to the Hinsdale Humane Society
Nov 8th, 2022
audience shot
AHA22
Trial results shed light on tool for assessing VTE risk, routine anticoagulation for non-hospitalized COVID patients, and clinical outcomes of open vs. endovascular surgery for advanced PAD
Nov 8th, 2022
audience shot
AHA22
Bivalirudin superior to unfractionated heparin in primary PCI following STEMI
Nov 8th, 2022
Panelists of the Mindful Disruption panel
Late-Breaking Science
Overcoming health disparities, health care advocates and mindfulness can better manage BP and CVD
Nov 7th, 2022
Medtech
AHA22
Medtech is getting smarter — and so is patient care
Nov 7th, 2022
med tech checking fluids in a hospital
AHA22
New digital hub offers professional education to complement lifelong learning
Nov 7th, 2022
Aha22 Sm 2334
AHA22
Trial results report on benefits of radial artery for CABG, use of prophylactic methylprednisolone and ECMO for patients in cardiogenic shock
Nov 7th, 2022
runner montage
AHA22
And the Health Tech Competition winner is…
Nov 7th, 2022
Aha Ss22 Days123 Pg1
AHA22
Read all about it
Nov 7th, 2022
Screen Shot 2022 11 06 At 10 45 03 Am
AHA22
Science, medicine must be a ‘relentless force’ in fighting misinformation
Nov 6th, 2022